Physician profile
Mrinalini E Matcha
NPI 1114952058
$6,000.80
in general payments reported to CMS, 2019-2025
33 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $369 · 2021: $862 · 2022: $1,163 · 2023: $1,319 · 2024: $1,133 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,797 · Education: $60.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,797.11 |
| Education | $60.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $854.18 | 2019-2024 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $608.31 | 2019-2025 | Rayaldee |
| Horizon Therapeutics Plc | $557.61 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $510.08 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $353.41 | 2021-2024 | |
| Amgen INC. | $329.24 | 2019-2025 | Krystexxa, Uplizna, Tavneos |
| Aurinia Pharma U.S., INC. | $323.38 | 2021-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $300.58 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $297.77 | 2019-2022 | |
| Travere Therapeutics, INC. | $293.40 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $203.21 | 2019-2024 | Velphoro |
| Lilly USA, LLC | $200.67 | 2023-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $170.90 | 2022-2024 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $126.75 | 2019-2025 | |
| Arbor Pharmaceuticals, INC. | $116.68 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.09 | 2023-2025 | Jardiance |
| Renalytix Ai, INC. | $78.36 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Mallinckrodt Hospital Products INC. | $76.84 | 2024-2025 | Terlivaz |
| Akebia Therapeutics INC | $63.18 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $58.69 | 2019 | |
| Alnylam Pharmaceuticals INC. | $57.28 | 2023-2025 | Givlaari, Onpattro |
| Kyowa Kirin, INC. | $48.50 | 2023-2024 | Crysvita |
| Cormedix INC. | $46.37 | 2024 | Defencath |
| Shire North American Group INC | $42.11 | 2019 | |
| Alexion Pharmaceuticals, INC. | $29.93 | 2020-2021 | |
| Medtronic, INC. | $22.54 | 2023 | Ellipsys Vascular Access System |
| Ultragenyx Pharmaceutical INC. | $21.38 | 2022 | |
| Ardelyx, INC. | $20.79 | 2025 | Ibsrela |
| Boston Scientific Corporation | $17.09 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Nuwellis, INC. | $16.32 | 2025 | Aquadex Smartflow Console |
| Shield Therapeutics INC | $15.94 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $13.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mrinalini Matcha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.